论文部分内容阅读
尽管纳米药物的应用正在进一步发展并已经走向市场,但迄今为止,纳米制药仍然被视为一项新兴技术,它的概念并不明了。纳米制药也可以解释为一种会聚技术,它结合多种技术特征,范围从纳米技术波及到医学和信息通信技术。它的特征是否会引起新的伦理问题,或者这些相关纳米制药的伦理问题仅仅是基础领域现存问题的延伸至今仍在争论之中。我们认为,不管关联的伦理问题新奇还是技术进步引致的发展,都影响纳米制药领域的利益相关者发挥这样的作用,即要求以不同的方式负责任地创新。关联纳米制药的特有特征和会聚技术引进的特征在要求以不同方式负责的利益相关者中引起角色转换。我们提出,价值敏感设计是利益相关者在新纳米药物开发的早期阶段负责任地参与解决道德问题的一个适宜框架。
Although the use of nanomedicine is further evolving and moving to the market, so far nanopharmaceuticals are still considered an emerging technology whose concept is not clear. Nanopharmaceuticals can also be interpreted as a converging technology that combines several technical features ranging from nanotechnology to medical and ICTs. Whether its characteristics lead to new ethical issues or whether the ethical issues associated with these nanophases are mere extensions of the existing ones in the basic fields is still under debate. We believe that regardless of the novelty of the associated ethical issues or the development resulting from technological advances, it affects the stakeholders in nanopharmaceuticals to play the role of requiring responsible innovations in different ways. The peculiar characteristics of associative nanopharmaceuticals and the features introduced by convergence technologies have led to role shifts in stakeholders who demand different ways of being responsible. We propose that value-sensitive design is a suitable framework for responsible stakeholder engagement in addressing ethical issues early in the development of new nanomedicine.